Paxlovid (Nirmatrelvir/Ritonavir) is an investigational SARS-CoV-2 protease inhibitor antiviral therapy that received an emergency use authorization (EUA) by the Food and Drug Administration (FDA). The agency confirmed that Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients who are at an increased risk of progressing to severe illness. The dosage recommended for this drug is three pills (one of ritonavir and two of nirmatrelvir) twice a day for a total of 30 pills.
They added that ...
paxlovid, antiviral, covid-19, nirmatrelvir, ritonavir
READ MORE